PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms

Poly (ADP‐ribose) polymerase (PARP) inhibitors have provided great clinical benefits to ovarian cancer patients. To date, three PARP inhibitors, namely, olaparib, rucaparib and niraparib have been approved for the treatment of ovarian cancer in the United States. Homologous recombination deficiency (HRD) and platinum sensitivity are prospective biomarkers for predicting the response to PARP inhibitors in ovarian cancers. Preclinical data have focused on identifying the gene aberrations that might generate HRD and induce sensitivity to PARP inhibitors in vitro in cancer cell lines or in vivo in patient‐derived xenografts. Clinical trials have focused on genomic scar analysis to identify biomarkers for predicting the response to PARP inhibitors. Additionally, researchers have aimed to investigate mechanisms of resistance to PARP inhibitors and strategies to overcome this resistance. Combining PARP inhibitors with HR pathway inhibitors to extend the utility of PARP inhibitors to BRCA‐proficient tumours is increasingly foreseeable. Identifying the population of patients with the greatest potential benefit from PARP inhibitor therapy and the circumstances under which patients are no longer suited for PARP inhibitor therapy are important. Further studies are required in order to propose better strategies for overcoming resistance to PARP inhibitor therapy in ovarian cancers.

• Publication year

  2019

• Venue

  Journal of Cellular and Molecular Medicine

• Publication date

  2019-01-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jcmm.14133PMID 30672100PMCID 6433712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms

  2019cited by this paper
• An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations

  2018cited by this paper
• Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.

  2018cited by this paper
• A PET imaging agent for evaluating PARP-1 expression in ovarian cancer

  2018cited by this paper
• RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

  2018cited by this paper
• The evolving landscape of predictive biomarkers of response to PARP inhibitors.

  2018cited by this paper
• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Therapeutic targeting and patient selection for cancers with homologous recombination defects

  2017cited by this paper
• Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

  2017cited by this paper
• Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors

  2017cited by this paper
• Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

  2017cited by this paper
• Niraparib for the treatment of ovarian cancer

  2017cited by this paper
• Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

  2017cited by this paper
• Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

  2017cited by this paper
• Niraparib in ovarian cancer: results to date and clinical potential

  2017cited by this paper
• University of Groningen Therapeutic targeting and patient selection for cancers with homologous recombination defects

  2017cited by this paper
• Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.

  2016cited by this paper
• Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.

  2016cited by this paper
• In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

  2016influential reference
• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

  2016influential reference
• Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

  2016cited by this paper
• Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models

  2016cited by this paper
• Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.

  2016cited by this paper
• Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib

  2016cited by this paper
• Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment

  2016cited by this paper
• ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells

  2016cited by this paper
• Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

  2015cited by this paper
• Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs

  2015cited by this paper
• Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.

  2015cited by this paper
• REV7 counteracts DNA double-strand break resection and affects PARP inhibition

  2015cited by this paper
• A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

  2015cited by this paper
• BRACAnalysis CDx as a companion diagnostic tool for Lynparza

  2015cited by this paper
• PI3K and cancer: lessons, challenges and opportunities

  2014cited by this paper
• Molecular Pathways Molecular Pathways : How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors ?

  2014cited by this paper
• DNA-PKcs activates the Chk2–Brca1 pathway during mitosis to ensure chromosomal stability

  2014cited by this paper
• Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

  2014cited by this paper
• Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.

  2014cited by this paper
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

  2014cited by this paper
• An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.

  2014cited by this paper
• VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.

  2014influential reference
• Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors*

  2014cited by this paper
• PARP inhibitors in ovarian cancer: current status and future promise.

  2014cited by this paper
• Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

  2014cited by this paper
• Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

  2013cited by this paper
• A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity

  2013cited by this paper
• Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

  2013cited by this paper
• The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

  2013cited by this paper
• Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

  2013influential reference
• ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.

  2013cited by this paper
• RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

  2013cited by this paper
• Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer

  2013influential reference
• Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

  2013cited by this paper
• Mechanisms of resistance to therapies targeting BRCA-mutant cancers

  2013cited by this paper
• Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

  2013cited by this paper
• The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.

  2012cited by this paper
• PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

  2012cited by this paper
• Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome

  2012cited by this paper
• Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

  2012cited by this paper
• Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.

  2012cited by this paper
• The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

  2012cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• Loss of function germline mutations in RAD51D in women with ovarian carcinoma.

  2012cited by this paper
• Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.

  2012cited by this paper
• BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair.

  2012cited by this paper
• Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

  2012cited by this paper
• Germline mutations in RAD51D confer susceptibility to ovarian cancer

  2011influential reference
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

  2011cited by this paper
• Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

  2011influential reference
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

  2011cited by this paper
• Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

  2011cited by this paper
• Disposition and Drug-Drug Interaction Potential of Veliparib (ABT-888), a Novel and Potent Inhibitor of Poly(ADP-ribose) Polymerase

  2011cited by this paper
• Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

  2011cited by this paper
• The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

  2010cited by this paper
• ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors

  2010cited by this paper
• Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target

  2010cited by this paper
• 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

  2010cited by this paper
• Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

  2010influential reference
• PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

  2010cited by this paper
• 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

  2010cited by this paper
• Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.

  2010cited by this paper
• Meta‐analysis of brain‐derived neurotrophic factor p.Val66Met in adult ADHD in four European populations

  2010cited by this paper
• An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair

  2009cited by this paper
• Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

  2009cited by this paper
• Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

  2009cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

  2008cited by this paper
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

  2008cited by this paper
• HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

  2007cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining.

  2006influential reference

• Tumor microenvironment and biomarker innovation in ovarian cancer: mechanistic insights into immune evasion, angiogenesis, and therapeutic resistance.

  2026cites this paper
• PARP inhibitor combined with platinum activates the cGAS-STING pathway to enhance anti-PD-L1 immunotherapy in lung adenocarcinoma.

  2026cites this paper
• Tumor cell-intrinsic PD-1 in malignant ascites drives ovarian cancer progression via MAPK/ERK signaling

  2026cites this paper
• Hybrid deep neural network with PCA based features optimization for enhancing brain tumor classification.

  2026cites this paper
• Real-world outcomes following PARP inhibitor maintenance in ovarian cancer by BRCA status: a retrospective cohort study

  2026cites this paper
• Regulation of ferroptosis in colorectal cancer through therapeutic modulation and miRNA targeting

  2026cites this paper
• Emerging roles of PARP-1 driven dual inhibitors in cancer therapy: SAR-guided strategies and synthetic lethality.

  2026cites this paper
• Poly(ADP-ribose) polymerase-1 (PARP1)-based dual inhibitors targeting cancer synthetic lethality (2022-present): advances and perspectives.

  2025cites this paper
• AS-IV inhibits the progression of ovarian cancer by targeting the circ_0124787/miR-6875-3p/IL-1β axis.

  2025cites this paper
• DNA repair pathways in ovarian cancer: Implications for therapy and resistance.

  2025cites this paper
• Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board

  2025cites this paper
• Enhancing PARP inhibitor efficacy in ovarian cancer: targeting the PI3K/AKT/mTOR pathway

  2025cites this paper
• Clinical relevance of PLK1 in epithelial ovarian cancer

  2025cites this paper
• AAV for ovarian cancer gene therapy

  2025cites this paper
• Upregulation of NR4A3 increases sensitivity to niraparib in ovarian cancer cells resistant to this drug

  2025cites this paper
• Secondary cytoreductive surgery for ovarian cancer recurrence and first-line maintenance therapy: A multicenter retrospective study.

  2025cites this paper
• Synergistic suppression of cholangiocarcinoma cells via DNA damage response and cell cycle arrest by dual targeting PARP and ATM in DNA damage repair pathway.

  2025cites this paper
• Combined Effects of Cytokine TRAIL-Based DR5-Specific Fusion Protein with Olaparib on Tumor Cell Lines with Different BRCA Mutation Status

  2025cites this paper
• Acute cardiac dysfunction in patients with ovarian cancer treated with Niraparib due to TFAM mutation: A case series and functional analysis.

  2025cites this paper
• Therapeutic Targeting in Ovarian Cancer: Nano-Enhanced CRISPR/Cas9 Gene Editing and Drug Combination Therapy

  2025cites this paper
• Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy

  2025cites this paper
• IL17A/F secreted by ASCT2-overexpression ovarian cancer cells contributes to immune escape through the suppression of natural killer (NK) cells cytotoxicity by the activation of c-JUN/ PTGS2 pathway.

  2025cites this paper
• Predictive and Prognostic Factors in Epithelial Ovarian Cancer: A Review

  2025cites this paper
• Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants

  2025cites this paper
• Mass Spectrometry-Based Proteomics Technologies to Define Endogenous Protein-Protein Interactions and Their Applications to Cancer and Viral Infectious Diseases.

  2025cites this paper
• Identification of CYP2B6 as a Novel Biomarker of HRD in Colon Adenocarcinoma through WGCNA and Machine Learning

  2025cites this paper
• Complete remission with olaparib in BRIP1-mutated metastatic high-grade pleomorphic sarcoma: case study and literature review – an example of a genomic profiling-based tumor treatment, in a cancer type with high unmet clinical need

  2025cites this paper
• Maintenance therapy for platinum-sensitive recurrent ovarian cancer with a history of PARPi administration

  2025cites this paper
• Global research trends in PARP inhibitors for ovarian cancer: a bibliometric analysis

  2025cites this paper
• Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

  2025cites this paper
• COMPUTATIONAL DRUG DESIGN AND MOLECULAR DYNAMICS OF PHENYL BENZAMIDE DERIVATIVES AS PARP-1 INHIBITORS FOR BREAST CANCER THERAPY

  2025cites this paper
• Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian Cancer

  2024cites this paper
• Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer

  2024cites this paper
• Strategie în cazul unei guşi multinodulare mari, în contextul unei confirmări recente postoperatorii a unui carcinom ovarian seros de risc înalt

  2024cites this paper
• Nucleolar Localization of the RNA Helicase DDX21 Predicts Survival Outcomes in Gynecologic Cancers

  2024cites this paper
• Modern Approaches and Future Perspectives on Breast and Ovarian Cancer Prevention Strategies in BRCA1 and BRCA2 Mutation Carriers: A Literature Overview

  2024cites this paper
• Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors.

  2024cites this paper
• PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives

  2024cites this paper
• NDC80 Kinetochore Complex Serves as a Potential Prognostic Predictor and Correlates with Immune Infiltrates in Epithelial Ovarian Cancer Patients

  2024cites this paper
• How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature

  2024cites this paper
• High-grade serous papillary ovarian carcinoma combined with nonkeratinizing squamous cell carcinoma of the cervix: a case report

  2024cites this paper
• Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review.

  2024cites this paper
• Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair

  2024cites this paper
• Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer

  2024cites this paper
• BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer

  2024cites this paper
• Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.

  2024cites this paper
• AICAR-loaded and panitumumab conjugated nanoparticles downregulate the expression of PD-L1 and enhance antitumor responses against ovarian cancer through the AMPK/STAT3 axis

  2024cites this paper
• The dysregulation of PARP9 expression is linked to apoptosis and DNA damage in gastric cancer cells

  2024cites this paper
• All-trans Retinoic Acid Sensitizes Epithelial Ovarian Cancer to PARP Inhibition after Exposure to Cisplatin

  2024cites this paper
• Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a BRCA1 mutation

  2024cites this paper
• Efficacy and safety of angiogenesis inhibitors combined with poly ADP ribose polymerase inhibitors in the maintenance treatment of advanced ovarian cancer: a meta-analysis

  2024cites this paper
• Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers

  2024cites this paper
• Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.

  2024cites this paper
• Features and complexity of treatment of BRCA-associated ovarian cancer, chronic disease: literature review

  2024cites this paper
• Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant BRCA1-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge

  2024cites this paper
• PARP inhibitors in prostate cancer: clinical applications

  2024cites this paper
• Molecular mechanism of PARP inhibitor resistance

  2024cites this paper
• Mechanism and rational combinations with GP‐2250, a novel oxathiazine derivative, in ovarian cancer

  2024cites this paper
• Dual-target EZH2 inhibitor: latest advances in medicinal chemistry.

  2024cites this paper
• Gramicidin, a Bactericidal Antibiotic, Is an Antiproliferative Agent for Ovarian Cancer Cells

  2023cites this paper
• Identification of novel potential homologous repair deficiency-associated genes in pancreatic adenocarcinoma via WGCNA coexpression network analysis and machine learning

  2023cites this paper
• An Analysis For Early Diagnosis To Detect Ovarian Cancer

  2023cites this paper
• Targeting TRIP13 for overcoming anticancer drug resistance (Review)

  2023cites this paper
• The dynamic process of covalent and non-covalent PARylation in the maintenance of genome integrity: a focus on PARP inhibitors

  2023cites this paper
• Discussion article: do we understand the role of local treatments after oligoprogression of ovarian cancer on PARP inhibitors?

  2023cites this paper
• PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues

  2023cites this paper
• New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions

  2023cites this paper
• Patient-derived organoids in ovarian cancer: Current research and its clinical relevance.

  2023cites this paper
• Mechanism-Based Suppression of Cancer by Targeting DNA-Replicating Enzymes.

  2023cites this paper
• Somatic Variants in DNA Damage Response Genes in Ovarian Cancer Patients Using Whole-exome Sequencing

  2023cites this paper
• Prognostic and Predictive Biomarkers in Familial Breast Cancer

  2023cites this paper
• The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer

  2023influential citation
• Molecular targets and therapeutic strategies for triple-negative breast cancer

  2023cites this paper
• Diagnosis and treatment of ovarian cancer in the light of modern molecular genetic achievements

  2023cites this paper
• Complex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy

  2022cites this paper
• Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.

  2022cites this paper
• Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review.

  2022cites this paper
• Advances of DNA Damage Repair-Related Drugs and Combination With Immunotherapy in Tumor Treatment

  2022cites this paper
• Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research

  2022cites this paper
• Mechanisms of chemotherapy resistance in ovarian cancer

  2022cites this paper
• Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair

  2022influential citation
• Automatic identification of drug sensitivity of cancer cell with novel regression-based ensemble convolution neural network model

  2022cites this paper
• PARP Inhibition and Beyond in BRCA-Associated Breast Cancer in Women: A State-Of-The-Art Summary of Preclinical Research on Risk Reduction and Clinical Benefits

  2022cites this paper
• Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines

  2022cites this paper
• Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• Whole genome and transcriptome analysis enhances precision cancer treatment options.

  2022cites this paper
• Attenuation of Muscle Damage, Structural Abnormalities, and Physical Activity in Respiratory and Limb Muscles following Treatment with Rucaparib in Lung Cancer Cachexia Mice

  2022cites this paper
• Small-Molecule–Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death

  2022cites this paper
• Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program

  2022cites this paper
• Ovarian cancer resistance to PARPi and platinum-containing chemotherapy

  2022cites this paper
• PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications.

  2022cites this paper
• BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside

  2022influential citation
• Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors

  2022cites this paper
• Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy

  2022cites this paper
• Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug–drug interaction study

  2022cites this paper
• Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!

  2022influential citation
• CRISPR/Cas9: A Molecular Tool for Ovarian Cancer Management beyond Gene Editing.

  2022cites this paper
• Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations

  2021cites this paper
• Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis

  2021cites this paper
• Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.

  2021cites this paper